Predominance of TH1 response in tumor bearing mice and cancer patients treated with AS101

Background Several studies have recently suggested that the immune response to malignant growths is regulated by distinct patterns of type 2 cytokine production. These cytokines, regulating the cytotoxic T-lymphocyte response in patients with advanced cancers, may be associated with disease progression, Evidence suggests that the T Helper 1 (TH1) and T Helper 2 (TH2) types of reaction are reciprocally regulated in vivo. The immunomodulator AS101 (ammonium trichloro[dioxoethylene-O,O']tellurate) was found to stimulate mouse and human cells to proliferate and secrete a variety of cytokines. Clinical trials using AS101 on cancer patients are now in progress, Purpose: The aim of this study was to evaluate the ability of AS101 to modulate TH1 and TH2 responses in tumor-bearing mice and in patients with advanced cancer. In addition, we investigated the association between the predominance of each type of response with the antitumoral effects of AS101. Methods: Mice into, which Lewis lung carcinoma (3LL) had been transplanted (n = 221) and cancer patients (n = 13) were treated with AS101 on alternate days, at 10 mu g/mouse intraperitoneally, or for the patients, at 3 mg/m(2) intravenously, The types were sarcoma, melanoma, and colon, lung, ovarian, and renal cancers, Cytokine levels were determined by immunoassay hits and compared with the paired Student's t test: in mice, they were tested in spleen cell supernatants; in humans, in sera and mononuclear cell supernatants, The chi-squared test was used to compare tumor volumes, All P values represent two-sided tests of statistical significance. Results: Our results show that treatment of mice and patients with AS101 results im a clear predominance ire TH1 responses, with a concomitant decrease in the TH2-type response, This was reflected by a significant enhancement in interleukin 2 (IL-2) and interferon gamma (IFN gamma) levels (P<.01) paralleled by a substantial decrease in IL-4 and IL-10 (P<.01). Moreover, the concentration of IL-12 was significantly increased (P<.01) ire AS101-treated patients who also showed enhanced levels of natural and lymphokine-activated killer cell-mediated cytotoxicity. The statistically significant increases in IL-2 and IFN gamma levels, paralleled by the pronounced decrease in IL-4 and IL-10 in the AS101-treated mice, were associated with its anatitumoral effects. In addition, systemic cotreatment of 3LL-transplanted mice with AS101 and anti-IL-12 antibodies partly abrogated the antitumoral effect of AS101, Conclusions: Immunotherapy with AS101 enhances TR1 function while interfering with the TH2 response, This TH1 trend may he related to the antitumor effects of AS101, Implications: Isolation and characterization of a distinct cytokine pattern in patients with advanced cancer treated with AS101 may contribute to the development of intervention strategies using this compound.